Rezzayo is an antifungal medicine used to treat adults with invasive candidiasis. Invasive candidiasis is a fungal infection caused by a yeast called Candida that has spread widely in the body and may also be present in the blood. Invasive candidiasis is rare, and Rezzayo was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 6 January 2021. Further information on the orphan designation can be found on the EMA website. Rezzayo contains the active substance rezafungin.
Therapeutic Indication
### Therapeutic indication Rezzayo is indicated for the treatment of invasive candidiasis in adults. Consideration should be given to official guidance on the appropriate use of antifungal agents.
Therapeutic Area (MeSH)
ATC Code
J02AX08
ATC Item
rezafungin acetate
Pharmacotherapeutic Group
Antimycotics for systemic use
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| rezafungin | N/A | Rezafungin |
EMA Name
Rezzayo
Medicine Name
Rezzayo
Aliases
N/ANo risk management plan link.
